Experts discuss the evolving treatment landscape in ALL and the role of immunotherapies like ADCs and CAR-T cells. They highlight the potential of targeted therapy and stopping therapy in pH positive ALL. The efficacy of cartizo for CNS infiltration and combination therapy for non-CNS EMD is discussed. The use of immunotherapies in ALL treatment is explored, including the benefits of combining therapies and optimizing immunotherapy. The effects of treatments on the immune system and tumor microenvironment in ALL are examined, including Punatine's impact on T-cells and NK-cells and the potential of LCK inhibition.